EP Patent

EP4034091A1 — Rifaximin liquid formulations

Assigned to Bausch Health Ireland Ltd · Expires 2022-08-03 · 4y expired

What this patent protects

Provided herein are pharmaceutical compositions which enhance the intestinal levels of soluble rifaximin, formulations comprising said compositions, and their use in treating one or more bowel related disorders.

USPTO Abstract

Provided herein are pharmaceutical compositions which enhance the intestinal levels of soluble rifaximin, formulations comprising said compositions, and their use in treating one or more bowel related disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4034091A1
Jurisdiction
EP
Classification
—
Expires
2022-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Bausch Health Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.